Advertisement

Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

Published:November 10, 2022DOI:https://doi.org/10.1016/j.clgc.2022.10.015

      Abstract

      Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published results support the use of taxanes, second-generation antiandrogens or radiotherapy to the primary tumor as part of the treatment in these patients, considering ADT alone as suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for oligometastatic patients in different tumor types. In oligometastatic hormone-sensitive prostate cancer the role of MDT is being studied with promising results. In the present review we assess the available evidence for radiotherapy to the primary tumor in newly diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions in this clinical setting.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ryan CJ
        • Smith MR
        • de Bono JS
        • et al.
        Abiraterone in metastatic prostate cancer without previous chemotherapy.
        N Engl J Med. 2013; 368: 138-148
        • Beer TM
        • Armstrong AJ
        • Rathkopf DE
        • et al.
        Enzalutamide in metastatic prostate cancer before chemotherapy.
        N Engl J Med. 2014; 371: 424-433
        • Fizazi K
        • Tran N
        • Fein L
        • et al.
        Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.
        N Engl J Med. 2017; 377: 352-360
        • Davis ID
        • Martin AJ
        • Stockler MR
        • et al.
        Enzalutamide with standard first-line therapy in metastatic prostate cancer.
        N Engl J Med. 2019; 381: 121-131
        • Armstrong AJ
        • Szmulewitz RZ
        • Petrylak DP
        • et al.
        A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.
        J Clin Oncol. 2019; 37: 2974-2986
        • Chi KN
        • Agarwal N
        • Bjartell A
        • et al.
        Apalutamide for metastatic, castration-sensitive prostate cancer.
        N Engl J Med. 2019; 381: 13-24
        • Satkunasivam R
        • Kim AE
        • Desai M
        • et al.
        Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis.
        J Urol. 2015; 194: 378-385
        • Löppenberg B
        • Dalela D
        • Karabon P
        • et al.
        The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis.
        Eur Urol. 2017; 72: 14-19
        • Boevé LMS
        • Hulshof MCCM
        • Vis AN
        • et al.
        Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial.
        Eur Urol. 2019; 75: 410-418
        • Parker CC
        • James ND
        • Brawley CD
        • et al.
        Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
        Lancet. 2018; 392: 2353-2366
      1. NCCN clinical practice guidelines in oncology. [Internet]. Pennsylvania, EEUU: National Comprehensive Cancer Network (NCCN); 2020 [actualizado enero 2022; citado 17 marzo 2022]. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

        • Cornford P
        • van den Bergh RCN
        • Briers E
        • et al.
        EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer.
        Eur Urol. 2021; 79: 263-282
        • Hellman S
        • Weichselbaum RR.
        Oligometastases.
        J Clin Oncol. 1995; 13: 8-10
        • Palma DA
        • Olson R
        • Harrow S
        • et al.
        Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
        Lancet. 2019; 393: 2051-2058
        • Sweeney CJ
        • Chen Y-H
        • Carducci M
        • et al.
        Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
        N Engl J Med. 2015; 373: 737-746
        • Burdett S
        • Boevé LM
        • Ingleby FC
        • et al.
        Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis.
        Eur Urol. 2019; 76: 115-124
      2. U.S. National Library of Medicine. ClinicalTrial.gov [Internet] U.S. National Library of Medicine; [acces data 14 april 2022]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01957436.

        • Ali A
        • Hoyle A
        • Haran ÁM
        • et al.
        Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer. A secondary analysis of a randomized clinical trial.
        JAMA Oncol. 2021; 7: 555-563
        • Ost P
        • Reynders D
        • Decaestecker K
        • et al.
        Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.
        J Clin Oncol. 2018; 36: 446-453
        • Ost P
        • Reynders D
        • Decaestecker K
        • et al.
        Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-years results of a randomized phase II trial.
        J Clin Oncol. 2020; 38 (10-10)
        • Phillips R
        • Shi W
        • Deek M
        • et al.
        Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial.
        JAMA Oncol. 2020; 6: 650-659
        • Deek MP
        • Van der Eecken K
        • Sutera P
        • et al.
        Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials.
        J Clin Oncol. 2022; 40: 3377-3382
        • Conde-Moreno AJ
        • Lopez F
        • Hervas A
        • et al.
        Phase II trial of SBRT and androgen deprivation for oligometastases in prostate cancer.
        Int J Rad Oncol Biol Phys. 2021; 111: S59
        • Supiot S
        • Vaugier L
        • Pasquier D
        • et al.
        OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer.
        Eur Urol. 2021; 80: 405-414
        • Jereczek-Fossa BA
        • Fanetti G
        • Fodor C
        • et al.
        Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes.
        Clin Genitourin Cancer. 2017; 15: 623-632
        • Marvaso G
        • Volpe S
        • Pepa M
        • et al.
        Recent advances in the management of hormone-sensitive oligometastatic prostate cancer.
        Cancer Manage Res. 2022; 14: 89-101
        • Mazzola R
        • Francolini G
        • Triggiani L
        • et al.
        Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness.
        Clin Genitourin Cancer. 2021; 19: 230-236
        • Siva S
        • Bressel M
        • Murphy DG
        • et al.
        Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial.
        Eur Urol. 2018; 74: 455-462
        • Viani GA
        • Arruda CV
        • Hamamura AC
        • et al.
        Stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. A meta-analysis.
        Am J Clin Oncol. 2020; 43: 73-81
        • Yan M
        • Moideen N
        • Bratti VF
        • Moraes FY.
        Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence.
        Br J Radiol. 2020; 93: 1-9
        • Ost P
        • Jereczek-Fossa BA
        • Van As N
        • et al.
        Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences.
        Clin Oncol R Coll Radiol G B. 2016; 28: 115-120
        • Annunziata S
        • Pizzuto DA
        • Treglia G.
        Diagnostic performance of PET imaging using different radiopharmaceuticals in prostate cancer according to published meta-analyses.
        Cancers (Basel). 2020; 12: 2153
        • Deek MP
        • Van der Eecken K
        • Phillips R
        • et al.
        The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited.
        Eur Urol. 2021; 80: 632-640
        • Deek MP
        • Taparra K
        • Dao D
        • et al.
        Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer.
        Int J Radiat Oncol Biol Phys. 2021; 109: 387-395
      3. U.S. National Library of Medicine. ClinicalTrial.gov [Internet] U.S. National Library of Medicine; [citado 20 de mar de 2022]. Disponible en: https://clinicaltrials.gov

        • Decaestecker K
        • De Meerleer G
        • Lambert B
        • et al.
        Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
        Radiat Oncol. 2014; 9: 135
        • Rischke HC
        • Schultze-Seemann W
        • Wieser G
        • et al.
        Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only.
        Strahlenther Onkol. 2015; 191: 310-320
        • Zilli T
        • Dirix P
        • Heikkilä R
        • et al.
        The multicenter, randomized, phase 2 PEACE V-STORM trial: defining the best salvage treatment for oligorecurrent nodal prostate cancer metastases.
        Eur Urol Focus. 2021; 7: 241-244